Medtronic Initiates Worldwide Pivotal Study to Evaluate its Extravascular Implantable Cardioverter Defibrillator System

 Medtronic Initiates Worldwide Pivotal Study to Evaluate its Extravascular Implantable Cardioverter Defibrillator System

Medtronic Initiates Worldwide Pivotal Study to Evaluate its Extravascular Implantable Cardioverter Defibrillator System

Shots:

  • Medtronic initiates global pivotal study evaluating its EV ICD system to treat dangerously fast heart rhythms in 400 patients at 60 sites across North America, Europe, the Middle East, Asia, Australia and New Zealand with the 1EPs as defibrillation testing success rate at the implant
  • The EV ICD pivotal study follows the chronic EV ICD pilot study, evaluated 21 patients in New Zealand and Australia and early research and acute feasibility studies including the ASD, SPACE & ASD2
  • The EV ICD system is designed to deliver lifesaving defibrillation and pacing therapy via a device the same size as traditional, transvenous ICDs, but with a lead (thin wire) placed outside the heart and veins

Click here to­ read full press release/ article | Ref: Medtronics | Image: Waterfall City

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post